Abstract:Over the past two decades, many pre-clinical and clinical studies have been conducted to establish stem cell therapy as a potential treatment for heart failure. Although the original purpose was to replace the scar lesion with new cardiomyocytes generated from stem cells, there is growing evidence that therapeutic benefits may be derived mostly from cardioprotective paracrine factors released by stem cells. Paracrine factors from several cell sources, including bone marrow-derived cells, endothelial cells, and mesenchymal stromal cells, have been shown to stimulate growth of new blood vessels and activate the endogenous repair pathway in the myocardium. Several studies hypothesized that these paracrine effects work through extracellular vesicles (EVs) secreted from stem cells. EVs, including exosomes and microvesicles, are released by different types of cells and involved in both physiological and pathophysiological processes. EVs are believed to mediate intercellular communication by transmitting information from the cells of origin to their target cells. Thus, attempts are being made to utilize EVs as novel tools for various therapeutic approaches such as antitumour and regenerative therapies, and some antitumour EVs have already entered phase II human clinical trials. Since the discovery of human induced pluripotent stem cells (iPSCs) by Shinya Yamanaka et al., they are increasingly being used in cardiovascular research for disease modelling, drug screening, personalized medicine, and regenerative medicine. Although previous studies have shown that transplantation of either human embryonic stem cell-derived cardiomyocytes (hESC-CMs) or iPSC-derived cardiomyocytes (iPSC-CMs) to non-human primates can engraft or improve cardiac function through direct cardiomyocyte replacement, there are still several hurdles to overcome, including short-term ventricular arrythmias and long-term sustainable engraftment. In this issue of the journal, El Harane et al. sought to test whether EVs secreted by iPSC-derived cardiovascular progenitors (iPSC-PGs) can recapitulate the therapeutic effects of direct transplantation of iPSC-PGs. They successfully isolated EVs from iPSC-PGs, and found that iPSC-CMs did not produce EVs althogh the mechanism is unclear. EVs were internalized in vitro to target cells, which improved cell survival and proliferation of cultured H9C2 cardiomyocytes, and promoted angiogenesis including scratch wound healing and tube formation. Similarly, in vivo EV injection improved cardiac function in a murine myocardial infarction model. Surprisingly, the injection of EVs outperformed transplantation of their parent progenitor cells. The EVs were enriched with 16 highly conserved microRNAs (miRNAs), which are associated with biological functions expected to ameliorate heart failure. In terms of target genes of the miRNAs, they showed that the hearts from the three groups treated with iPSC-CMs, iPSCPGs, and EVs showed distict gene expression patterns. The work by El Harane et al. highlights the effect of EVs secreted by iPSC-PGs on chronic heart failure following myocardial infarction. In terms of clinical application, these results have three important implications. First, the source of EVs is progenitor cells differentiated from iPSCs, which are more available than hESCs from the ethical point of view. Second, the EV therapy is considered to be relatively safe because it is a cell-free therapy. Third, EV therapy was more effective in improving cardiac function in vivo than the direct transplantation of parent stem cells. In their previous studies, Kervadec et al. showed that the injection of EVs secreted from human embryonic stem cell-derived cardiovascular progenitor cells (hESC-PGs) could provide beneficial effects equivalent to those of cell transplantation therapy of parent hESCPGs in the treatment of chronic heart failure in mice.. While EV

Unravelling the ageing-reversal potency of stem cell-derived extracellular vesicles in a rat model of premature cardiac senescence

Stem cell therapy in the aging hearts of Fisher 344 rats: Synergistic effects on myogenesis and angiogenesis

Rejuvenating effects of young extracellular vesicles in aged rats and in cellular models of human senescence

Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells.

Antiapoptotic Effect of Implanted Embryonic Stem Cell-Derived Early-Differentiated Cells in Aging Rats after Myocardial Infarction.

Aged‐senescent cells contribute to impaired heart regeneration

Small extracellular vesicles from young adipose-derived stem cells ameliorate age-related changes in the heart of old mice.

Lack of Cardiac Improvement after Cardiosphere-Derived Cell Transplantation in Aging Mouse Hearts

Embryonic stem cell-derived extracellular vesicles rejuvenate senescent cells and antagonize aging in mice

3D ECM-Based Scaffolds Boost Young Cell Secretome-Derived EV Rejuvenating Effects in Senescent Cells

Extracellular Vesicles from Healthy Cells Improves Cell Function and Stemness in Premature Senescent Stem Cells by miR-302b and HIF-1α Activation

Extracellular Vesicles and Cardiac Aging

Rat Induced Pluripotent Stem Cells Protect H9C2 Cells from Cellular Senescence Via a Paracrine Mechanism

Investigating the Paracrine Role of Perinatal Derivatives: Human Amniotic Fluid Stem Cell-Extracellular Vesicles Show Promising Transient Potential for Cardiomyocyte Renewal

Small Extracellular Vesicles Isolated from Cardiac Tissue Matrix or Plasma Display Distinct Aging-Related Changes in Cargo Contributing to Chronic Cardiovascular Disease

Embryonic Stem Cell-Derived Extracellular Vesicles Enhance the Therapeutic Effect of Mesenchymal Stem Cells.

Enhancing cellular regeneration through targeted pharmacological reprogramming of senescent endothelial cells

Advanced Age Impairs Cardioprotective Function of Mesenchymal Stem Cell Transplantation from Patients to Myocardially Infarcted Rats

ESC‐sEVs Rejuvenate Senescent Hippocampal NSCs by Activating Lysosomes to Improve Cognitive Dysfunction in Vascular Dementia

CD133+ endothelial-like stem cells restore neovascularization and promote longevity in progeroid and naturally aged mice

Induced Pluripotent Stem Cells As a Biopharmaceutical Factory for Extracellular Vesicles